| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2025 | ANIP Ani Pharmaceuticals Inc | Mutz Christopher | Head Of Rare Disease | Sell | 4,000 | $60.45 | $241,800.00 | -3.6% | +46.3% | +31.8% | |
| May 14, 2025 | APUS Apimeds Pharmaceuticals Us, Inc. | Kim Christopher | Chairman And CMO | Buy | 27,500 | $1.83 | $50,359.20 | +139.1% | -13.4% | -26.3% | |
| May 13, 2025 | LFCR Lifecore Biomedical, Inc. \de\ | English Aron R.50 | 10% Owner | Sell | 12,334 | $7.00 | $86,352.80 | -0.7% | +3.9% | -35.3% | |
| May 13, 2025 | EBS Emergent Biosolutions Inc. | Papa Joseph C | President And CEO | Buy | 60,000 | $5.83 | $349,800.00 | +21.2% | +38.8% | +41.7% | |
| May 13, 2025 | EOLS Evolus, Inc. | Beaver Sandra67 | Chief Financial Officer | Sell | 6,494 | $10.02 | $65,069.88 | -3.7% | -43.0% | -33.7% | |
| May 13, 2025 | ANIP Ani Pharmaceuticals Inc | Cook Meredith50 | Sr. VP, General Counsel &Sec. | Sell | 400 | $62.20 | $24,880.00 | -0.5% | +36.9% | +30.5% | |
| May 13, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 2,872 | $27.03 | $77,630.16 | -2.9% | +27.9% | +130.9% | |
| May 13, 2025 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Sell | 15,000 | $26.13 | $391,904.00 | -5.6% | +28.4% | - | |
| May 12, 2025 | PRGO Perrigo Co Plc | Parker Geoffrey M.46 | Director | Buy | 3,500 | $27.10 | $94,850.00 | +17.3% | -18.4% | -58.8% | |
| May 12, 2025 | TSNDF Terrascend Corp. | Schutter Edward J | Director | Buy | 1,041,021 | $0.39 | $405,998.19 | +67.8% | - | - | |
| May 12, 2025 | APUS Apimeds Pharmaceuticals Us, Inc. | Koo Jakap | Director | Buy | 28,500 | $1.99 | $56,715.00 | +4.6% | -15.5% | -26.0% | |
| May 12, 2025 | HIMS Hims & Hers Health, Inc. | Baird Melissa | Chief Operating Officer | Sell | 33,333 | $56.02 | $1,867,376.22 | -1.0% | -9.5% | -54.7% | |
| May 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Kiely John | Director | Sell | 50,000 | $7.59 | $379,500.00 | -16.3% | +16.3% | +65.8% | |
| May 12, 2025 | VTRS Viatris Inc | Smith Scott Andrew94 | Chief Executive Officer | Buy | 60,000 | $8.94 | $536,262.00 | +25.8% | +10.0% | +91.6% | |
| May 12, 2025 | EOLS Evolus, Inc. | Moatazedi David67 | See Remarks | Sell | 15,787 | $9.87 | $155,756.12 | -3.1% | -42.2% | -34.9% | |
| May 12, 2025 | APUS Apimeds Pharmaceuticals Us, Inc. | Inscobee Inc. | 10% Owner | Buy | 500,000 | $4.00 | $2,000,000.00 | +33.7% | -15.5% | -26.0% | |
| May 12, 2025 | EOLS Evolus, Inc. | Avelar Rui67 | See Remarks | Sell | 3,385 | $9.87 | $33,396.75 | -0.9% | -42.2% | -34.9% | |
| May 12, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 3,235 | $56.00 | $181,160.00 | -2.0% | -9.5% | -54.7% | |
| May 12, 2025 | BSPK Bespoke Extracts, Inc. | Feinsod Michael | CEO | Buy | 2,000 | $0.11 | $210.00 | - | - | - | |
| May 12, 2025 | LFCR Lifecore Biomedical, Inc. \de\ | English Aron R.50 | 10% Owner | Sell | 51,496 | $7.03 | $362,019.16 | -1.0% | +3.4% | - | |
| May 9, 2025 | UTHR United Therapeutics Corp | Thompson Tommy G51 | Director | Sell | 2,500 | $305.15 | $762,865.00 | -22.8% | -0.7% | +87.4% | |
| May 9, 2025 | BMY Bristol Myers Squibb Co | Hickey Benjamin | President, Rayzebio Org. | Sell | 97 | $38.01 | $3,701.83 | -100% | -2.3% | +20.9% | |
| May 9, 2025 | ANIP Ani Pharmaceuticals Inc | Shanmugam Muthusamy59 | Head Of R&D, Coo-novitium Ops | Sell | 700 | $76.83 | $53,781.00 | -0.1% | +4.1% | +23.5% | |
| May 9, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Patel Sanj K | Chairman &CEO | Sell | 8,095 | $27.04 | $218,866.45 | -2.7% | +27.2% | +125.1% | |
| May 8, 2025 | TEVA Teva Pharmaceutical Industries Ltd | Sabag Mark | See "remarks" | Sell | 337,915 | $18.04 | $6,097,304.47 | -69.1% | -11.4% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.